Chemours - CC Stock Forecast, Price & News

10 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Chemours in the last year. There are currently 1 sell rating, 6 hold ratings and 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" CC shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in CC, but not buy additional shares or sell existing shares.
View CC analyst ratings or view top-rated stocks.

10 brokers have issued 12 month price targets for Chemours' shares. Their CC share price forecasts range from $27.00 to $43.00. On average, they anticipate the company's share price to reach $36.33 in the next twelve months. This suggests a possible upside of 26.2% from the stock's current price.
View analysts price targets for CC or view top-rated stocks among Wall Street analysts.

Chemours' stock was trading at $30.62 at the beginning of the year. Since then, CC shares have decreased by 5.9% and is now trading at $28.80.
View the best growth stocks for 2023 here.

Chemours saw a increase in short interest in February. As of February 28th, there was short interest totaling 4,480,000 shares, an increase of 7.7% from the February 13th total of 4,160,000 shares. Based on an average daily trading volume, of 1,060,000 shares, the short-interest ratio is presently 4.2 days. Approximately 3.1% of the shares of the stock are short sold.
View Chemours' Short Interest.

The company is scheduled to release its next quarterly earnings announcement on Monday, May 1st 2023.
View our CC earnings forecast.

The Chemours Company (NYSE:CC) posted its quarterly earnings results on Thursday, November, 4th. The specialty chemicals company reported $1.27 earnings per share for the quarter, beating the consensus estimate of $0.99 by $0.28. The specialty chemicals company had revenue of $1.68 billion for the quarter, compared to analysts' expectations of $1.58 billion. Chemours had a net margin of 8.51% and a trailing twelve-month return on equity of 61.75%. The firm's quarterly revenue was up 36.3% compared to the same quarter last year. During the same quarter in the prior year, the company earned $0.47 earnings per share.

Chemours announced a quarterly dividend on Monday, February 6th. Shareholders of record on Friday, February 24th will be given a dividend of $0.25 per share on Wednesday, March 15th. This represents a $1.00 annualized dividend and a dividend yield of 3.47%. The ex-dividend date is Thursday, February 23rd.
Read our dividend analysis for CC.

ETFs with the largest weight of Chemours (NYSE:CC) stock in their portfolio include ProShares Smart Materials ETF (TINT), First Trust Materials AlphaDEX Fund (FXZ), Alpha Architect U.S. Quantitative Value ETF (QVAL), BlackRock Future U.S. Themes ETF (BTHM), Invesco DWA Basic Materials Momentum ETF (PYZ), First Trust Dorsey Wright Momentum & Value ETF (DVLU), Invesco S&P MidCap Value with Momentum ETF (XMVM) and First Trust Dorsey Wright Momentum & Dividend ETF (DDIV).

Chemours (NYSE:CC) pays an annual dividend of $1.00 per share and currently has a dividend yield of 3.43%. The dividend payout ratio is 28.01%. This payout ratio is at a healthy, sustainable level, below 75%. Based on earnings estimates, CC will have a dividend payout ratio of 20.70% next year. This indicates that the company will be able to sustain or increase its dividend.
Read our dividend analysis for CC.

Chemours updated its FY23 earnings guidance on Thursday, February, 9th. The company provided earnings per share guidance of $3.80-4.29 for the period, compared to the consensus estimate of $4.06.

106 employees have rated Chemours Chief Executive Officer Mark Vergnano on Glassdoor.com. Mark Vergnano has an approval rating of 85% among the company's employees.

Based on aggregate information from My MarketBeat watchlists, some companies that other Chemours investors own include AT&T (T), Pfizer (PFE), DuPont de Nemours (DD), NVIDIA (NVDA), Cisco Systems (CSCO), Micron Technology (MU), Intel (INTC), AbbVie (ABBV), CVS Health (CVS) and Energy Transfer (ET).

Chemours trades on the New York Stock Exchange (NYSE) under the ticker symbol "CC."

Chemours' stock is owned by many different retail and institutional investors. Top institutional shareholders include LSV Asset Management (1.96%), JPMorgan Chase & Co. (1.91%), Dimensional Fund Advisors LP (1.55%), Geode Capital Management LLC (1.38%), AQR Capital Management LLC (1.13%) and Norges Bank (1.02%). Insiders that own company stock include Alisha Bellezza, Alvenia Scarborough, David C Shelton, Denise Dignam, Edwin C Sparks, Edwin C Sparks, Mark Newman, Mark P Vergnano, Mark P Vergnano, Matthew S Abbott and Sameer Ralhan.
View institutional ownership trends.

Shares of CC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of CC stock can currently be purchased for approximately $28.80.

Chemours (NYSE:CC) has a market capitalization of $4.29 billion and generates $6.79 billion in revenue each year. The specialty chemicals company earns $578 million in net income (profit) each year or $3.57 on an earnings per share basis.

The company employs 6,600 workers across the globe.

Chemours' mailing address is 1007 MARKET STREET, WILMINGTON DE, 19801. The official website for the company is www.chemours.com. The specialty chemicals company can be reached via phone at (302) 773-1000 or via email at investor@chemours.com.